Sign inJoin waitlistJoin the waitlist

Kevin Camphausen

Chief · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Clinical Center at the National Institutes of Health
Present

Research

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
The Journal of Experimental Medicine · 2006 · 1,465 citations
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
Journal of Clinical Oncology · 2009 · 1,277 citations
Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer
Journal of Clinical Oncology · 2006 · 430 citations

Andra Krauze
43 papers
Deborah Citrin
37 papers
CC
C. Coleman
18 papers
MM
Megan Mackey
18 papers
Ying Weatherall
18 papers
Aradhana Kaushal
16 papers
Nicole Simone
12 papers · 9 as a resident
Peter Choyke
9 papers
WK
Whoon Jong Kil
9 papers · 4 as a resident
PM
Peter Mathen
8 papers
DeeDee Smart
7 papers
James Gulley
7 papers

Grants

Radiation Oncology Branch - Radiation Clinic
National Cancer Institute · ZID
Contact PI · $136M · Division of Basic Sciences - Nci
The Synergy Between Radiotherapy and Molecularly Targeted Agents
National Cancer Institute · ZIA
Contact PI · $22.2M · Division of Clinical Sciences - Nci
Radiation Oncology Branch - Microarray Facility
National Cancer Institute · ZIC
Contact PI · $13.8M · Division of Basic Sciences - Nci
Pre-Clinical Development of Radiation Sensitizers for Patients with Glioblastoma
National Cancer Institute · ZIA
Contact PI · $12M · Division of Clinical Sciences - Nci

Clinical trials

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2021–2026
Managing Cancer and Living Meaningfully (CALM) Therapy in Individuals Diagnosed With a Primary Brain Tumor
Principal investigator · Completed
National Cancer Institute (NCI)
2021–2024
Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2020–2028
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
2017–2022